New Research Reports

Quarterly Update Q2FY26

Management expects a gradual demand recovery in H2FY26E, supported by improving macro indicators and internal execution initiatives.

IndusInd Bank is undergoing a strategic recalibration under new leadership, balancing near-term prudence with medium-term growth ambitions.

Rossari Biotech continues to execute well operationally, leveraging R&D intensity and export expansion to offset pricing headwinds.

Colgate’s Q2FY26 result reaffirms that business remains structurally fatigued, with no visible triggers for a turnaround. Revenue declined 6.2% YoY, implying a 7-8% volume decline amid GST-led destocking and continued competitive intensity.

END OF DAY SUMMARY

Retail Research

MARKET SNAPSHOT

Quarterly Update Q2FY26

Quarterly Update Q2FY26

Colgate’s (CLGT) 2QFY26 performance remained weak as its revenue fell 6% YoY to INR15.2b (in line) on a high base of 10% growth and due to the impact of GST-led transition (trade disruptions).

Laurus Lab (LAURUS) delivered yet another better-than-expected quarter with a 6%/18%/38% beat on revenue/EBITDA/PAT. Higher formulation sales (FDF; backed by robust ARV revenue), a superior mix in the CDMO segment, and improving operating leverage led to a strong 2QFY26 performance.

Broad-based expansion in its Cables & Wires business boosted Polycab India’s Q2 revenue 18% y/y. Operating leverage, product premiumisation and a favourable mix gave it its highest quarterly margins.

Retail Research

Retail Research

Acutaas Chemicals registered a superlative performance in Q2FY26. Revenue, EBITDA and PAT registered strong growth of 24%,95% and 94% respectively on YoY terms. We believe the company will can clock in revenue CAGR of 25-30% for the next 2 years with margins upwards of 29%. The growth will be propelled by strong growth in the advanced pharma intermediates business owing to strong traction in CDMO business and targeting of more molecules which will go off patent. We believe that strong traction in key molecules will continue along with further scale up of CDMO business with the increasing ramp up of the...

We maintain our BUY recommendation on the stock

Asian markets are trading lower, tracking Wall Street's declines on concerns about U.S.-China trade relations. The Nikkei is trading down 1.28%, the Hang Seng is trading down 0.39%, and the Shanghai Composite is trading down 0.46%.